The Future of Drug Discovery: Embracing AI for faster, personalised medicine

The future of drug discovery is no longer confined to the lab bench. It lies in the realm of intelligent algorithms, powerful computing, and the boundless creativity of generative AI. By embracing this technological leap, we can welcome in a new era of faster, more efficient, and personalized medicine, bringing hope and healing to millions around the world. 

The path to AI-driven drug discovery is not without its challenges. But for those bold enough to embrace the challenge, the rewards are immense. Generative AI is not just a technological marvel; it’s a beacon of hope, promising a future where life-saving medicines reach patients faster, personalized treatments become the norm, and the fight against disease is waged with the power of artificial intelligence on our side. Innodata’s team of AI specialists bridge the gap between scientific aspirations and technological realities transforming your potential into tangible results.  

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:

More articles like this

POLB 001: Targeting CRS in Cancer Immunotherapy

Phase 2 Ready orally administered p38 MAP Kinase inhibitor – a preventative therapy targeting an addressable market of more than $10 billion. POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer

Poolbeg Pharma updates on Immunomodulator II Patent

Poolbeg Pharma has announced that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a precursor to the expected formal grant

February hires in Pharma

February may be the shortest month, but we got an extra day this year and that left plenty of time for personnel announcements in the pharma world. Read on for a roundup of the month’s hiring

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a